Abstract：Objective To evaluate the clinical efficacy and analyze relevant prognostic factors of simultaneous integrated boost intensity-modulated radiation therapy (SIB-IMRT) for esophageal squamous cell carcinoma. Methods A total of 101 patients diagnosed with esophageal squamous cell carcinoma received SIB-IMRT from 2009 to 2015. The prescribed dose of PTV was 5040 cGy/28 times (180 cGy/time) and the dose for planning gross tumor volume (PGTV) was 6020 cGy/28 times (215 cGy/time) or 6160 cGy/28 times (220 cGy/time) simultaneously. The total treatment time was 5.5 weeks (once a day,5 times a week).The adverse events, mode of treatment failure,l-,3-and 5-year local control (LC) and overall survival (OS) rates were observed. Results The quantity of patients who completed the 1-,3-and 5-year follow-up was 101, 84 and 45, respectively. The 1-,3-and 5-year LC rates were 81.6%,70.4% and 68.4%, respectively. The 1-,3-and 5-year OS rates were 72.3%,49.4% and 45.2%, respectively. The median survival time was 36 months. Univariate and multivariate analyses showed that clinical staging (stage Ⅰ/Ⅱ/Ⅲ) and tumor response (complete remission/ partial remission/no remission) were the prognostic factors of OS (P=0.016,0.000,0.005,0.000).There were no significant differences in the LC and OS between the two groups of 215 cGy and 220 cGy (P=0.283,0.951).The incidence rates of grade 1,2,3 acute pneumonitis were 10.9%(11/101),2.0%(2/101) and 2.0%(2/101), respectively. The incidence rates of grade 1,2,3 acute esophagitis were 63.4%(64/101),10.9%(11/101) and 4.0%(4/101), respectively. No acute esophageal perforation or hemorrhage occurred. Five patients experienced late pneumonitis (two died). One case developed late lemostenosis, two cases developed esophageal perforation and hemorrhage, and two patients experienced esophageal hemorrhage. The patients treated with a fractionated dose of 220 cGy had a higher incidence rate of acute pneumonitis and upper gastrointestinal adverse reactions than those receiving 215 cGy (P=0.062,0.024).The local failure and recurrence accounted for 62.5% of all treatment-related failures. Conclusions SIB-IMRT yields high long-term clinical efficacy and tolerable adverse events in the treatment of esophageal squamous cell carcinoma. Compared with the dose of 215 cGy, the fractionated dose of 220 cGy fails to improve LC and OS rates, whereas enhances the risk of adverse events. The clinical staging and short-term clinical efficacy are the prognostic factors of survival rate.
Bai Wenwen,Song Yuzhi,Qiao Yongzhi et al. Clinical efficacy and prognostic factors of simultaneous integrated boost intensity-modulated radiation therapy for esophageal squamous cell carcinoma[J]. Chinese Journal of Radiation Oncology, 2018, 27(6): 570-575.
[1] 陈万青,郑荣寿,张思维,等.2013年中国恶性肿瘤发病和死亡分析[J].中国肿瘤,2017,26(1):1-7.DOI:10.11735/j.issn.1004-0242.2016.01.A001. Chen WQ,Zheng RS,Zhang SW,et al. Report of cancer incidence and mortality in China,2013[J].China Cancer,2017,26(1):1-7.DOI:10.11735/j.issn.1004-0242.2016.01.A001. [2] Welsh J,Palmer MB,Ajani JA,et al. Esophageal cancer dose escalation using a simultaneous integrated boost technique[J].Int J Radiat Oncol Biol Phys,2012,82(1):468-474.DOI:10.1016/j.ijrobp.2010.10.023. [3] Fakhrian K,Oechsner M,Kampfer S,et al. Advanced techniques in neoadjuvant radiotherapy allow dose escalation without increased dose to the organs at risk:planning study in esophageal carcinoma[J].Strahlenther Onkol,2013,189(4):293-300.DOI:10.1007/s00066-012-0297-7. [4] 中国非手术治疗食管癌临床分期专家小组.非手术治疗食管癌的临床分期标准(草案)[J].中华放射肿瘤学杂志,2010,19(3):179-180.DOI:10.3760/cma.j.issn.1004-4221.2010.03.001. Group of experts on clinical staging of non-surgical treatment of esophageal cancer in China. Standard for clinical staging of non-surgical treatment of esophageal cancer (draft)[J].Chin J Radit Oncol,2010,19(3):179-180.DOI:10.3760/cma.j.issn.1004-4221.2010.03.001. [5] 肖泽芬.食管癌[A]//殷蔚伯,谷铣之.肿瘤放疗学[M].3版.北京:中国协和医科大学出版社,2002:598-620. Xiao ZF.Esophageal cancer[A]//Yin WB,Gu XZ.Radiation Oneology[M].3rd ed. Beijing:Peking Union Medical College Press,2002:598-620. [6] Cox JD,Stetz J,Pajak TF.Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)[J].Int J Radit Oncol Biol Phys,1995,31(5):1341-1346.DOI:10.1016/0360-3016(95)00060-C. [7] 万钧.食管癌放疗后复发的再治疗[A]//万钧,韩春,刘惠明.食管癌的放疗[M].2版.北京:原子能出版社,2006:157-160. Wan J.Recurrent treatment of esophageal carcinoma after radiotherapy[A]//Wan J,Han C,Liu HM.Radiotherapy for esophageal cancer[M].2 ed. Beijing:Atomic press,2006:157-160. [8] 王澜,孔洁,韩春,等.781例不同部位食管癌三维放疗预后分析[J].中华放射肿瘤学杂志,2013,22(1):18-21.DOI:10.3760/cma.j.issn.1004-4221.2013.01.006. Wang L,Kong J,Han C,et al. Prognostic analysis of cervical,upper-thoracic,middle-thoracic,and lower-thoracic esophageal cancers in 781 patients mainly receiving three-dimensional radiotherapy[J].Chin J Radiat Oncol,2013,22(1):18-21.DOI:10.3760/cma.j.issn.1004-4221.2013.01.006. [9] 谭立君,肖泽芬,张红星,等.不能手术食管癌三维放疗与同期放化疗生存比较[J].中华放射肿瘤学杂志,2015,24(2):106-110.DOI:10.3760/cma.j.issn.1004-4221.2015.02.002. Tan LJ,Xiao ZF,Zhang HX,et al. Survival comparison of three-dimensional radiotherapy alone with concurrent chemoradiotherapy for non-surgical esophageal carcinoma[J].Chin J Radiat Oncol,2015,24(2):106-110.DOI:10.3760/cma.j.issn.1004-4221.2015.02.002. [10] 白文文,周志国,甄婵军,等.159例颈及胸上段食管癌调强放疗长期疗效分析[J].中华放射医学与防护杂志,2016,36(1):28-34.DOI:10.3760/cma.j.issn.0254-5098.2016.01.005. Bai WW,Zhou ZG,Zhen CJ,et al. Long-term efficacy of 159 cases of cervical and upper esophageal carcinoma treated with intensity-modulated radiotherapy[J].Chin J Radiol Med Prot,2016,36(1):28-34.DOI:10.3760/cma.j.issn.0254-5098.2016.01.005. [11] 朱孝贞,尹淑玲,陈秋立,等.2722例食管癌放疗分析[J].中国放射肿瘤学,1988,2(4):18-19. Zhu XZ,Yin SL,Chen QL,et al. Radiotherapy of carcinoma of esophagus-an analysis of 2722 cases[J].Chin J Radiat Oncol,1988,2(4):18-19. [12] Rastogi M,Sapru S,Gupta P,et al. Prospective evaluation of Intensity Modulated Radiation Therapy with Simultaneous Integrated Boost (IMRT-SIB) in head and neck squamous cell carcinoma in patients not suitable for chemo-radiotherapy[J].Oral Oncol,2017,67:10-16.DOI:10.1016/j.oraloncology.2017.01.005. [13] 于长华,王万伟,朱卫国,等.颈及胸上段食管癌同时整和加量调强放疗分析[J].肿瘤防治研究,2010,37(5):575-577,585.DOI:10.3971/j.issn.1000-8578.2010.05.023. Yu CH,Wang WW,Zhu WG,et al. SIB-IMRT for neck and upper thoracic esophageal carcinoma[J].Cancer Res Prev Treat,2010,37(5):575-577,585.DOI:10.3971/j.issn.1000-8578.2010.05.023. [14] 陈志明,薛强,陈晓珏,等.同步加量调强放疗联合尼妥珠单抗治疗局部晚期食管癌[J].中华放射肿瘤学杂志,2016,96(8):640-642.DOI:10.3760/cma.j.issn.0376-2491.2016.08.012. Chen ZM,Xue Q,Chen XY,et al. Short-term efficacy and toxicity of Nimotuzumab combined with simultaneous integrated boost intensity-modulated radiotherapy for locally advanced esophageal cancer[J].Chin J Radiat Oncol,2016,96(8):640-642.DOI:10.3760/cma.j.issn.0376-2491.2016.08.012. [15] 张芹,吴培培,苗亚丽,等.同步整合加量调强放疗治疗颈及胸上段食管癌的临床观察[J].现代肿瘤医学,2017,25(10):1568-1571.DOI:10.3969/j.issn.1672-4992.2017.10.014. Zhang Q,Wu PP,Miao YL,et al. The clinical observation of the imultaneously integrated boost intensity-modulated radiotheragy in cervical and upper thoracic esophageal carcinoma[J].J Modern Oncol,2017,25(10):1568-1571.DOI:10.3969/j.issn.1672-4992.2017.10.014. [16] Yu WW,Zhu ZF,Fu XL,et al. Simultaneous integrated boost intensity-modulated radiotherapy in esophageal carcinoma:early results of a phase Ⅱ study[J].Strahlenther Onkol,2014,190(11):979-986.DOI:10.1007/s00066-014-0636-y. [17] Xu YJ,Wang Z,Liu G,et al. The efficacy and safety of simultaneous integrated boost intensity-modulated radiation therapy for esophageal squamous cell carcinoma in Chinese population:a single institution experience[J].J Cancer Res Ther,2016,12(5):82-88.DOI:10.4103/0973-1482.191640. [18] 白文文,宋玉芝,刘明,等.SIB-IMRT技术在颈及胸上段食管癌中的临床应用[J].中华肿瘤防治杂志,2016,23(4):248-252.DOI:10.16073/j.cnki.cjcpt.2016.04.010. Bai WW,Song YZ,Liu M,et al. Clinical application of simultaneous integrated boost intensity-modulated radiation therapy in cervical and upper esophageal carcinoma[J].Chin J Radiol Med Prot,2016,23(4):248-252.DOI:10.16073/j.cnki.cjcpt.2016.04.010. [19] Bednarek C,Crehange G,Quivrin M,et al. Mapping of failures after radiochemotherapy in patients with non-metastatic esophageal cancer:a posteriori analysis of the dose distribution in the sites of loco-regional relapse[J].Radiother Oncol,2015,116(2):252-256.DOI:10.1016/j.radonc.2015.07.019. [20] Minsky BD,Pajak TF,Ginsberg RJ,et al. INT 0123(Radiation Therapy Oncology Group 94-05) phase Ⅲ trial of combined-modality therapy for esophageal cancer:high-dose versus standard-dose radiation therapy[J].J Clin Oncol,2002,20(5):1167-1174.DOI:10.1200/JCO.2002.20.5.1167. [21] Chen JZ,Guo H,Zhai TT,et al. Radiation dose escalation by simultaneous modulated accelerated radiotherapy combined with chemotherapy for esophageal cancer:a phase Ⅱ study[J].Oncotarget,2016,7(16):22711-22719.DOI:10.18632/oncotarget.8050. [22] Yu W,Cai XW,Liu Q,et al. Safety of dose escalation by simultaneous integrated boosting radiation dose within the primary tumor guided by 18FDG-PET/CT for esophageal cancer[J].Radiother Oncol,2015,114(2):195-200.DOI:10.1016/j.radonc.2014.12.007. [23] Oh D,Noh JM,Nam H,et al. High-dose radiation therapy alone by moderate hypofractionation for patients with thoracic esophageal squamous cell carcinoma[J].Medicine,2016,95(33):e4591.DOI:10.1097/MD.0000000000004591.
2018, Vol. 27 
